Hema Biologics

Executive Summary

Hema Biologics is a private U.S. biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare bleeding disorders. The company achieved a major milestone with the FDA approval of SEVENFACT® (coagulation factor VIIa recombinant-jncw) for the treatment of bleeding episodes in patients with hemophilia A or B with inhibitors, as well as congenital factor VII deficiency. Leveraging this approved product, Hema Biologics continues to advance a pipeline of investigational candidates targeting unmet medical needs in the rarest coagulation disorders. With a focus on patient support and disease education, the company is positioned to capture significant market share in the niche bleeding disorder space. As a private entity, Hema Biologics relies on strategic partnerships and revenue from SEVENFACT to fund ongoing R&D and expand its portfolio.

Upcoming Catalysts (preview)

• Q4 2026SEVENFACT label expansion to new indications or age groups45% success
• Q2 2027Phase 3 data readout for next-generation long-acting factor therapy55% success
• Q3 2026Strategic partnership or licensing deal for pipeline candidate35% success